<DOC>
	<DOC>NCT01854437</DOC>
	<brief_summary>Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.</brief_summary>
	<brief_title>The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>hemodialysis with duration&gt;3 months serum P level &gt;5.5 mg/dl serum Ca&gt;8 mg/dl. Mg level &gt;3 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>mg oxide</keyword>
	<keyword>hyperphosphatemia</keyword>
	<keyword>plasma phosphor level</keyword>
</DOC>